- Rubric Capital Management has boosted the number of nominees it is backing for Mereo BioPharma ( NASDAQ: MREO ) to five .
- The fifth nominee is Rubric founder David Rosen.
- In a letter to shareholders, Rosen wrote that "the problems on the Board of Mereo ( MREO ) run deeper than we anticipated."
- The letter also criticizes Mereo's ( MREO ) Board for rejecting "our request for a special meeting based on the flimsiest of pretexts."
- Rubric owns ~14% of the company's outstanding shares. The stock is up 4% in Monday afternoon trading.
- In September, Mereo ( MREO ) slammed Rubric for rejecting an offer to put a Rubric principal and another director on the company's board .
For further details see:
Rubric Capital boosts Mereo BioPharma board nominees slate to five